mylife Diabetes Care AG
9
6
6
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 9 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (9)
Menstrual Cycle Mapping While Using Closed-Loop Insulin Delivery
Role: collaborator
Impact of the Mylife CamAPS FX System With the DEXCOM G6 Sensor on T1D Patients in France
Role: lead
Early Feasibility Evaluation of the UniBE Hybrid Closed-loop Insulin Delivery System in Type 1 Diabetes: UBLoop-Genesis
Role: collaborator
Automated Insulin Delivery Versus Usual Insulin Treatment Modality Before and During Pregnancy in Women With Type 1 Diabetes
Role: collaborator
Evaluation of Neurodevelopmental Trajectories in Children According to the Glycemic Profile Associated With Different Early Treatment Modalities in Children With Type 1 Diabetes (T1DM)
Role: collaborator
Insulin Pump Versus Full Closed-loop for Type 2 Diabetes
Role: collaborator
French National Cohort of People With Type 1 Diabetes
Role: collaborator
YpsoPump Occlusion Detection Algorithm: Collection of Real-world Data for In-silico Evaluation of a New Software Algorithm to Refine Occlusion Detection in Subjects With Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion
Role: lead
Extended Wear of a Steel and a Teflon Insulin Infusion Set
Role: lead
All 9 trials loaded